- PhD, University College London, 2012
Education & Training
My research program is focused on investigating the genetic, molecular, cellular, and behavioral contributions underlying the divergence of neurodegenerative disorders including Alzheimer’s disease from healthy Aging. My laboratory is a critical component of several NIA-funded multi-institutional Open Science consortia including MODEL-AD, TREAT-AD, and MARMO-AD. Building on my drug discovery expertise and 18-year tenure in the pharmaceutical industry, a major goal of my research is to identify tractable targets as therapeutic interventions by the development and comprehensive phenotypic characterization of genetic animal models including mice and marmosets in order to understand divergence of disease progression from normal healthy aging and as model systems to evaluate potential therapeutic interventions. We are also focused on using pharmacological and genetic tools coupled with multi-omics approaches to interrogate biological targets that may be drivers of the divergence of normal healthy aging towards pathogenesis and progression of neurodegeneration, dementia, and cognitive decline.
Sukoff Rizzo SJ. Recent advances in model systems for interrogating diseases of brain aging and associated dementia: towards human relevant endophenotypes. Current Opinion in Neurobiology, accepted, in press.
Yang T, Huhe H, Williams S-P, Kaur S, Ay YA, Davis-Gilbert ZW, Cary GA, Butler RR, Wiley J, Betarbet R, Fu H, Duong D, Seyfried NT, Leal K, Carter GW, Edwards A, Levey AI, Capener JL, Drewry DH, Hossain MA, Oh HJ, Axtman AD, Sukoff Rizzo SJ, Longo FM. PAK1 inhibitor NVS-PAK1-1 preserves dendritic spines in amyloid/tau exposed neurons and 5xFAD mice. Alzheimer’s & Dementia, accepted, in press.
Sukoff Rizzo SJ, Homanics G, Schaeffer DJ, Schaeffer L, Park JE, Oluoch J, Zhang T, Haber A, Seyfried NT, Paten B, Greenwood A, Murai T, Choi SH, Huhe H, Kofler J, Strick PL, Carter GW, Silva AC. Bridging the rodent to human translational gap: Marmosets as model systems for the study of Alzheimer's disease. Alzheimers Dement (N Y). 2023 Aug 21;9(3):e12417. doi: 10.1002/trc2.12417. PMID: 37614242; PMCID: PMC10442521.
Huhe H, Shapley SM, Duong D, Wu F, Ha SK, Choi SH, Kofler J, Mou Y, Guimaraes TR, Thathiah A, Schaeffer LKH, Carter GW, Seyfried NT, Silva AC, Sukoff Rizzo SJ. Marmosets as model systems for the study of Alzheimer's disease and related dementias: substantiation of physiological Tau 3R and 4R isoform expression and phosphorylation. Alzheimers Dement. 2024 Nov 19. doi: 10.1002/alz.14366.
Murai TM, Bailey L, Schultz L, Mongeau L, DeSana A, Roberts AC, Silva AC, Sukoff Rizzo SJ. Improving preclinical to clinical translation of cognitive function for Aging Related Disorders: the utility of comprehensive touchscreen testing batteries in common marmosets. Cogn Affect Behav Neurosci. 2024 Apr;24(2):325-348. doi: 10.3758/s13415-023-01144-x. Epub 2024 Jan 10. PMID: 38200282; PMCID: PMC11039501.
Homanics G, Park JE, Bailey L, Schaeffer DJ, Schaeffer L, He J, Li S, Zhang T, Haber A, Spruce C, Greenwood A, Murai T, Schultz L, Mongeau L, Ha S-K, Oluoch J, Stein B, Choi SH, Huhe H, Thathiah A, Strick PL, Carter GW, Silva AC, Sukoff Rizzo SJ. Early molecular events of autosomal dominant Alzheimer’s disease in marmosets with PSEN1 mutations. Alzheimers Dement. 2024 May;20(5):3455-3471. doi: 10.1002/alz.13806. Epub 2024 Apr 4. PMID: 38574388; PMCID: PMC11095452.
Kotredes KP, Pandey RS, Persohn S, Elderidge K, Burton CP, Miner EW, Haynes KA, Santos DFS, Williams SP, Heaton N, Ingraham CM, Lloyd C, Garceau D, O'Rourke R, Herrick S, Rangel-Barajas C, Maharjan S, Wang N, Sasner M, Lamb BT, Territo PR, Sukoff Rizzo SJ, Carter GW, Howell GR, Oblak AL. Characterizing molecular and synaptic signatures in mouse models of late-onset Alzheimer's disease independent of amyloid and tau pathology. Alzheimers Dement. 2024 Jun;20(6):4126-4146. doi: 10.1002/alz.13828. Epub 2024 May 12. PMID: 38735056; PMCID: PMC11180851.
Oblak, A, Cope ZA, Quinney SK, Pandey R, Biesdorf C, Masters AR, Onos KD, Haynes L, Keezer K, Meyer JA, Peters J, Persohn SC, Bedwell AA, Eldridge K, Speedy R, Little G, Noarbe B, Obenaus A, Williams S-P, Sasner M, Howell GR, Carter GW, Williams H, Lamb BT, Territo PR, Sukoff Rizzo SJ. Prophylactic Evaluation of Verubecestat on disease and symptom modifying effects in 5XFAD Mice. (2022). Alzheimers Dement (N Y). 2022 Jul 14;8(1):e12317. doi: 10.1002/trc2.12317. PMID: 35846156; PMCID: PMC9281365.
